
Laboratorios ERN joins the Fundación Empresa y Clima (FEC) as a Silver member
We are proud to announce that Laboratorios ERN has officially joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing our commitment to climate action and global sustainability This alliance allows us to become part of a business community committed to the transition toward a low-carbon economy, alongside other companies that share the...
ERN Laboratories supports research into pediatric rare diseases at Sant Joan de Déu Hospital in Barcelona.
During 2026, ERN Laboratories will allocate €1 for each unit sold of Astenolit Infantil, a nutritional supplement designed to support children’s energy levels and immune defenses, to benefit pediatric rare disease research at Sant Joan de Déu This initiative is part of ERN Laboratories’ longstanding commitment to pediatrics and child health,...
Ernamín at the 55th Congress of the Spanish Society of Nephrology
From October 16–18, the 55th edition of the Congress of the Spanish Society of Nephrology (SEN) took place in Oviedo For the first time, and following the launch of Ernamín, ERN Laboratories participated as a collaborator in the event, with a stand in the commercial exhibition area and by organizing a technical forum featuring high-level speakers The...
Incremental Drug Innovation: A Priority Focus for Laboratorios ERN
David Solanes López, General Manager of Laboratorios ERN, was appointed Academician of the Royal Academy of Pharmacy of Catalonia on October 6, 2025, in the industrial section Solanes dedicated his induction speech to incremental innovation, an area closely linked to his professional career and to Laboratorios ERN’s commitment to developing solutions...
FDA has approved intravenous fosfomycin for the treatment of cUTI
On October 22, 2025, the US Food and Drug Administration (FDA) approved intravenous fosfomycin for the treatment of complicated urinary tract infections (cUTI) Laboratorios ERN expresses its satisfaction with the recent approval by the US Food and Drug Administration (FDA) of intravenous fosfomycin for the treatment of patients aged 18 years and older...
Laboratorios ERN collaborates with the Master’s in Logistics and Supply Chain Management at the University of Barcelona
The collaboration with the Institut de Formació Contínua–IL3 allows students to apply their knowledge to a real case in the pharmaceutical sector Laboratorios ERN has strengthened its ties with the academic field through a collaboration with the Master’s in Logistics and Supply Chain Management at the Institut de Formació Contínua–IL3, part of...
“A Rose Not to Forget”
Once again, on the occasion of Sant Jordi's Day, April 23rd, 2025, Laboratorios ERN has renewed its commitment to solidarity by joining the Fundació Alzheimer Catalunya As we did in 2024, we wanted to convey a message of support to all people affected by Alzheimer's disease Each rose delivered represents much more than a flower: it is a living symbol of...
Laboratorios ERN’s Presence at the Meeting with the President of the Spanish Government
David Solanes López, General Director of Laboratorios ERN, met on February 12, 2025, with the President of the Government of Spain, Pedro Sánchez, along with other executives from the national and multinational pharmaceutical industry, Farmaindustria, EFPIA, and the Minister of Health, Mónica García, the Minister of Industry, Jordi Hereu, and other...
Biocat reaffirms its leadership in innovation with the first Board of Trustees meeting under Salvador Illa’s Presidency
Barcelona, December 17, 2024 Biocat, the strategic driver of the life sciences and healthcare sector in Catalonia, held a historic Board of Trustees meeting on December 17 at the Palau de la Generalitat This meeting marked a milestone, being the first under the new Catalan Government administration and with Salvador Illa, President of the Government of...